OXiGENE has announced that Dr. Timothy Lai presented encouraging data from the FAVOR study of Zybrestat in polypoidal choroidal vasculopathy (PCV) at the 6th Asia-Pacific VitreoRetina Society (APVRS) Congress in India in December 2011. FAVOR is a Phase 2 study investigating the use of a single intravenous injection of Zybrestat at different...

OXiGENE has initiated a phase 2 study of its vascular-disrupting agent ZYBRESTAT (fosbretabulin) for treating patients with polypoidal choroidal vasculopathy (PCV), the company announced in a press release. PCV is a form of choroidal neovascularization characterized by the growth of abnormal blood vessels in the choroid and is similar to wet...